Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY

This observational study is following patients in Italy who are starting treatment with Epidyolex (a prescription cannabis-based medicine containing cannabidiol/CBD) for one of three serious epilepsy conditions: Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC). The goal is to track how well it works in real-world clinical practice. **You may be eligible if...** - You are an adult, or a child aged 2 or older - You have been diagnosed with Lennox-Gastaut Syndrome, Dravet Syndrome, or Tuberous Sclerosis Complex - Your doctor has made the clinical decision to start you on Epidyolex as part of your regular care - You (or your parent/guardian) are willing and able to give consent **You may NOT be eligible if...** - You have used recreational cannabis, medical cannabis, or other cannabinoid products in the past 3 months and are unwilling to stop during the study - Your doctor determines Epidyolex is not appropriate based on safety warnings (such as certain liver function abnormalities) Talk to your doctor to see if this trial is right for you.